Wednesday, 22 September 2010

Positive benefit-risk profile for multiple sclerosis candidate Laquinimod in phase IIb extension study - update

From the MS Trust:

Teva Pharmaceutical Industries Ltd and Active Biotech reported Monday that a 36-week phase IIb extension study of Laquinimod in the treatment of relapsing remitting multiple sclerosis or RRMS demonstrated sustained positive benefit-risk profile.  For more click here.